Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults
Open Access
- 1 July 2007
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 9 (3) , 354-363
- https://doi.org/10.1215/15228517-2007-006
Abstract
Preclinical evidence suggests that continuous low-dose daily (metronomic) chemotherapy may inhibit tumor endothelial cell proliferation (angiogenesisKeywords
This publication has 62 references indexed in Scilit:
- Angiogenesis and apoptosis in glioma: Two arenas for promising new therapiesJournal of Cellular Biochemistry, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiformeZeitschrift für Krebsforschung und Klinische Onkologie, 2004
- The anti-angiogenic basis of metronomic chemotherapyNature Reviews Cancer, 2004
- Phase II Trial of Thalidomide and Carmustine for Patients With Recurrent High-Grade GliomasJournal of Clinical Oncology, 2003
- SU6668 inhibits Flk‐1/KDR and PDGFRβ in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in miceThe FASEB Journal, 2002
- Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicityJournal of Clinical Investigation, 2000
- Effects of Basic Fibroblast Growth Factor on in Vivo Cerebral Tumorigenesis in RatsNeurosurgery, 1997
- Angiogenesis in malignant gliomasGlia, 1995
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994